Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
07:00am, Wednesday, 09'th Oct 2024
Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO , Oct. 9, 2024 /PRN
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
05:29am, Monday, 07'th Oct 2024
The investment bank analysts who follow these stocks think they can soar even further, with some caveats.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
06:51pm, Friday, 04'th Oct 2024
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $64.96, denoting a +1.33% change from the preceding trading day.
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
08:00am, Friday, 04'th Oct 2024
Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
06:56pm, Thursday, 03'rd Oct 2024
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $64.11, marking a -0.9% move from the previous day.
Is Viking Therapeutics Ready For Another Surge?
03:00pm, Wednesday, 02'nd Oct 2024
Viking Therapeutics VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial
Why Viking Therapeutics Stock Topped the Market Today
06:34pm, Monday, 30'th Sep 2024
An analyst waxed bullish on the company's leading pipeline program.
Is Viking Therapeutics Stock a Buy?
08:30am, Sunday, 29'th Sep 2024
Investors have piled into the biotech because of its weight-loss drug candidate. There are already some hugely successful products on pharmacy shelves.
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
07:03am, Saturday, 28'th Sep 2024
Viking Therapeutics and Summit Therapeutics both have potential blockbusters on their hands. Their shares have soared this year on the back of strong clinical progress.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
06:51pm, Friday, 27'th Sep 2024
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $61.68, marking a -1.03% move from the previous day.
Is Viking Therapeutics Ready For Another Surge?
07:30am, Friday, 27'th Sep 2024
Viking Therapeutics NASDAQ: VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinic
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
06:55pm, Wednesday, 25'th Sep 2024
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $63.13, representing a +1.94% change from its previous close.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
06:08pm, Wednesday, 25'th Sep 2024
An analyst reiterated his optimistic stance on the biotech. Like many others, he feels its leading investigational drug has great potential.
Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable Risks
05:18pm, Wednesday, 25'th Sep 2024
Viking Therapeutics' weight-loss drug VK2735 shows strong efficacy, likely leading to an acquisition by a large pharmaceutical firm, in my opinion. But the firm faces significant risks and competition
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
11:37am, Wednesday, 25'th Sep 2024
Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Nov
